Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
ALXO Stock Chart & Stats
$1.70
$0.01(0.54%)
At close: 4:00 PM EST
$1.70
$0.01(0.54%)
Day’s Range― - ―
52-Week Range$0.40 - $2.27
Previous CloseN/A
Volume579.15K
Average Volume (3M)678.47K
Market Cap
$99.07M
Enterprise Value-$40.95M
Total Cash (Recent Filing)$79.31M
Total Debt (Recent Filing)$3.04M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 06, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding53,551,132
10 Day Avg. Volume619,089
30 Day Avg. Volume678,473
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.41
Enterprise Value/Revenue-47.17
Enterprise Value/Gross Profit213.26
Enterprise Value/Ebitda0.35
Forecast
1Y Price Target
$2.00Price Target Upside17.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Enrollment And AnalysisEnrollment into the ASPEN-BREAST trial is anticipated to begin soon, with an interim analysis planned to provide additional insights.
Market OpportunityData suggests that 50-70% of HER2+ breast cancer patients overexpress CD47, representing a large market opportunity for ALX Oncology if the study is successful.
Program PrioritizationManagement's decision to prioritize high-conviction programs is seen as prudent in the current financial environment.
Trial DesignALX Oncology is updating the design of its Phase 2 ASPEN-Breast study to enable a CD47 and HER2 biomarker-driven strategy, which could enhance the trial's effectiveness.
Bears Say
Resource AllocationALX has decided not to move forward with the planned Phase 1 ASPEN-CRC study, indicating a need to better prioritize cash resources.
Study Design ChallengesThe single-arm design of the new study may make the data more difficult to interpret compared to the prior plan for a randomized control trial.
ALX Oncology Holdings News
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $0.40 and its highest was $2.27 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
ALX Oncology Holdings’s market cap is $99.07M.
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is Nov 06, 2025 which is in 21 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on Aug 12, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.422 by -$0.068.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -0.37.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 53,551,132 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.422. Following the earnings report the stock price went up 6.452%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Currently, no hedge funds are holding shares in ALXO
ALX Oncology Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (17.65% Upside)
$2.00 (17.65% Upside)
Blogger Sentiment
Bullish
ALXO Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 96.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $156.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 9.7%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.67%
12-Months-Change
Fundamentals
Return on Equity
-104.21%
Trailing 12-Months
Asset Growth
-55.59%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
ALXO Company Deck
ALXO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook with significant advances in clinical programs, especially with the CD47 biomarker-driven strategy that shows promise for targeted oncology approaches. The extension of the cash runway and progress in partnered studies further strengthen the company's position. However, challenges remain in defining specific biomarker cutoffs and addressing unmet needs in HER2-positive breast cancer. Overall, the call suggests optimism for future developments.View all ALXO earnings summariesALXO Stock 12 Month Forecast
Average Price Target
$2.00
▲(17.65% Upside)
Technical Analysis
Adverum Biotechnologies
―
InflaRx
―
Quince Therapeutics
―
Adagene
―
Context Therapeutics
―
Ownership Overview
2.98% Insiders
4.47% Mutual Funds
36.67% Other Institutional Investors
53.42% Public Companies and
Individual Investors